Abstract
Epithelial ovarian carcinoma has a relatively low survival rate due to the fact that this disease is often diagnosed after it has already progressed to stage III or stage IV, thus making the disease more difficult to treat. In order to successfully metastasize to these regional and distant sites, tumor cells must be able to overcome extracellular matrix (ECM)-detachment-induced effects, including combatting increased reactive oxygen species (ROS). Here, we investigate peroxiredoxin 1 (PRDX1) and find that PRDX1 plays an important role in proliferation in ECM-attached and ECM-detached SKOV3 cells, an epithelial ovarian carcinoma cell line. Furthermore, we find that PRDX1 deficiency in SKOV3 cells promotes a substantial decrease in cell viability in ECM detachment contributing to abrogated cell growth in anchorage independence. Thus, our study finds that PRDX1 deficiency uniquely compromises cell viability in ECM-detached cells, suggesting that PRDX1 could be a potential therapeutic target for late-stage epithelial ovarian carcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.